Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CSA fine for J&J

This article was originally published in The Tan Sheet

Executive Summary

Johnson & Johnson will pay $511,000 in fines because imports of pseudoephedrine-containingBenedryl-D to a manufacturing facility in Lititz, Pa., were not reported as required by the Controlled Substances Act, according to an Aug. 5 settlement with the Department of Justice. The U.S. Attorney's Office for the Eastern District of Pennsylvania and J&J subsidiary McNeil-PPC explain the unreported imports of the OTC nasal decongestant tablets occurred during 2001 to 2005, when Pfizer's Warner-Lambert business owned the facility. J&J acquired the facility in 2006 when it bought Pfizer Consumer Healthcare (1"The Tan Sheet" Dec. 18, 2006, p. 9). DOJ says the CSA requires companies to file reports with the Drug Enforcement Agency within 15 days of importing products containing pseudophedrine and other specified chemicals that can be used in manufacturing controlled substances...

You may also be interested in...

J&J, Pfizer Satisfy FTC Conditions To Clear Deal; EC Signs Off

Johnson & Johnson and Pfizer's divestiture of the Zantac, Cortizone, Unisom and Balmex brands satisfies the Federal Trade Commission's anticompetitive complaint about J&J's acquisition of Pfizer's consumer healthcare business

Epizyme’s Tazverik Gets To Market In Rare Sarcoma, Paving Way To Bigger Indications

Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.

Shuttered US Supplement Firm Meets Recall Deadline, But Schumer Says FDA Late Cleaning Up Industry

While contract manufacturer ABH Nature' complied with consent decree, Sen. Chuck Schumer says FDA is late in enforcing against noncompliant firms across the supplement sector. Other recent consumer health recalls include more OTC ranitidine tablets due to the potential carcinogen NDMA found in the heartburn ingredient and four versions of Sure 48HR Anti-Perspirant & Deodorant with labeling errors.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts